FDA Clears Bayer's Low-Dose MRI Contrast Agent Ambelvist

FDA approved Bayer's low-dose macrocyclic gadolinium-based contrast agent Ambelvist (gadopiclenol). Its high relaxivity permits a lower gadolinium dose for MRI, potentially reducing patient exposure.

• Ambelvist (gadopiclenol) is a macrocyclic GBCA with high relaxivity, approved for use in adults and children.
• The low-dose formulation may decrease cumulative gadolinium burden while maintaining diagnostic image quality.
• This is a new agent in the U.S. market; clinical adoption and long-term safety data are pending.

RadPigeon summaries are original and for information only. They are not clinical advice.